Amendments to the Claims

This listing of claims will replace all prior listings of claims in the application.

Listing of Claims

- 1. (Currently Amended) A substance, characterized in that it is a polycyclic macrolactone and can be which is produced by a representative of the bacterial genus Verrucosispora.
- 2. (Currently Amended) A substance as claimed in claim 1, characterized in that it exhibits exhibiting a pharmacological effect, in particular an antibiotic effect comprising the polycyclic macrolactone of Claim 1.
- 3. (Currently Amended) A substance as claimed in claim 1, characterized in that it exhibits exhibiting an antibiotic effect towards Gram-positive bacteria, comprising the polycyclic macrolactone of Claim 1.
- 4. (Currently Amended) A substance The polycyclic macrolactone as claimed in Claim 1, characterized in that wherein the representative of the bacterial genus Verrucosispora is the bacterial strain AB 18-032 (DSM 15899).
- 5. (Currently Amended) A substance, in particular as elaimed in The polycyclic macrolactone of Claim 1, characterized by having the general structure of Formula \pm (I) together with all the possible relative configurations

where X is C=O or C-OH,

$$^{\text{OH}}$$
 Y is $^{\text{O-}}$ or $^{\text{C=O}}$

Z is
$$C=N--or$$
 CH or CH_2 .

6. (Currently Amended) A substance as claimed in claim 5The polycyclic macrolactone of Claim 5, characterized by having the structure of Formula II—together with all the possible relative configurations

7. (Currently Amended) A substance as claimed in elaim 5The polycyclic macrolactone of Claim 5, characterized by having the structure of Formula III—together with all the possible relative configurations

(III)
$$H_3^{16}$$
 CH_3 CH_3

8. (Currently Amended) A substance as claimed in claim 5The polycyclic macrolactone of Claim 5, characterized by having the structure of Formula IV together with all the possible relative configurations

(IV)
$$H_3^{16}C$$
 OH CH_3 OH $OH_3^{17}C$ OH OH OH

- 9. (Currently Amended) A substance, in particular as claimed in Claim 1, characterized in that it which inhibits the synthesis of para-aminobenzoic acid, in particular the synthesis of para-aminobenzoic acid from chorismic acid, comprising the polycyclic macrolactone of Claim 1.
- 10. (Currently Amended) A substance, in particular as claimed in Claim 1, characterized in that it is a The polycyclic macrolactone and, as constituent structures, exhibits of Claim 1, containing at least one oxabicyclo system and at least one Michael system as a double bond system.
 - 11. (Canceled)

- 12. (Currently Amended) A pharmaceutical composition characterized in that it comprises comprising at least one substance polycyclic macrolactone as claimed in Claim 1 and at least one pharmaceutically acceptable excipient.
- 13. (Currently Amended) A pharmaceutical composition characterized in that it comprises comprising at least one substance which inhibits the synthesis of para-aminobenzoic acid from chorismic acid and at least one pharmaceutically acceptable excipient.
- 14. (Currently Amended) The use of a substance as claimed in Claim 1 for A method of treating infectious diseases in a subject which are at least concomitantly influenced by bacteria and/or protozoa, comprising the step of administering to the subject the polycyclic macrolactone of Claim 1.

15.-21. (Canceled)

- 22. (Previously Presented) A microorganism, characterized in that it is able to produce at least one substance as claimed in Claim 1.
- 23. (Original) A microorganism as claimed in claim 22, characterized in that it is a strain of the bacterial genus *Verrucosispora*, or a mutant thereof.
- 24. (Previously Presented) A microorganism, in particular as claimed in claim 22, characterized in that it is the strain AB 18-032 (DSM 15899) of the bacterial genus Verrucosispora, or a mutant thereof.
- 25. (Previously Presented) A process for preparing at least one substance comprising the procedural steps of:
 - a) culturing a microorganism as claimed in Claim 22,

- b) obtaining a culture supernatant from the culture,
- c) where appropriate, preparing a culture filtrate, and
- d) where appropriate, isolating one or more substances from the culture supernatant and/or the culture filtrate.
- 26. (Currently Amended) A process for preparing the at least one substance as claimed in Claim 22, comprising the procedural steps of:
- a) culturing <u>athe</u> microorganismas claimed in Claim 22, and
- b) isolating one or more substances from the microorganism.
- 27. (New) A method of treating infectious diseases in a subject which are at least concomitantly influenced by bacteria or protozoa, comprising the step of administering to the subject a substance which inhibits the synthesis of paraaminobenzoic acid from chorismic acid.
- 28. (New) The method of Claim 14, wherein at least some of the bacteria are Gram-positive bacteria.
- 29. (New) The method of Claim 27, wherein at least some of the bacteria are Gram-positive bacteria.
- 30. (New) The method of Claim 14, wherein the bacteria or protozoa are multiresistant to antibiotics.
- 31. (New) The method of Claim 27, wherein the bacteria or protozoa are multiresistant to antibiotics.
- 32. (New) A microorganism capable of producing the polycyclic macrolactone of Claim 1.
- 33. (New) The microorganism of Claim 32, wherein said microorganism is a strain or mutant of *Verrucosispora*.

34. (New) The microorganism of Claim 32, wherein said microorganism is *Verrucosispora* AB 18-032 or a mutant thereof.